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Sir,
Chechlin ˜ska et al raised an important issue regarding the detection
of minimal residual disease in cancer patients: the presence of
activated lymphoid cells in the blood and tumours of cancer patients.
Despite the fact that activated lymphoid cells are present near and
inside tumour tissues as well as in the blood of cancer patients, there
is no published evidence that these cells express Mammaglobin A,
NY-BR-1 or cytokeratin-19 (CK-19). In our study, we used 13
negative controls, peripheral blood lymphocytes from healthy donors
(n¼10) and three lymph nodes from patients with conditions other
than breast cancer. All three lymph nodes were biopsied in order to
rule out lymphoma and the histopatological diagnosis was reactive-
inflammatory lymph nodes. None of the markers used in our study
was expressed in any of the three inflammatory lymph nodes.
The high sensitivity and low specificity of the PCR detec-
tion methods may be due to contamination, – illegitimate
transcription and other causes such as the presence of cells
other than cancer cells expressing the same tumour antigens.
However, in every biological assay, a risk of false positive
results exists. The way to reduce this risk is to include more
molecular markers and utilize quantitative real-time PCR that will
be able to quantitate the amounts of RNA amplified. We are now in
the process of analysing larger cohort of patients with more
molecular markers using real-time PCR in order to correlate the
presence of MRD detected by RT–PCR to patients’ survival. We
will adopt the idea raised by Chechlin ˜ska et al and will also add to
our control group PBLs obtained from patients with inflammatory
conditions.
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